Marta G. M.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 1 Evaluation of SGN-ALPV in Patients with Advanced Solid Tumors Including GEJ Carcinoma, NSCLC, Gastric, Cervical, Ovarian, and Endometrial Cancers
- Phase 1 Dose Escalation and Cohort Expansion Study of Anti-PD-1 Monoclonal Antibody TSR-042 in Advanced Solid Tumors
- Phase I Evaluation of [177Lu]Lu-FF58 in Patients with Recurrent Glioblastoma Multiforme, Advanced Pancreatic Ductal Adenocarcinoma, and Gastroesophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 162 of 320 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator focuses on hormone‑receptor‑positive, HER2‑positive and triple‑negative disease across early‑stage and metastatic contexts.
- Hormone‑receptor‑positive Breast Cancer
- HER2‑positive Breast Cancer
- Triple‑negative Breast Cancer
- Adjuvant Breast Cancer strategies after neoadjuvant therapy
- Resistance after CDK4/6 inhibition in Breast Cancer
Efforts emphasize biomarker‑guided combinations and long‑term disease‑free survival outcomes.
Thoracic Oncology
Work in this area spans non‑small cell lung cancer, small‑cell lung cancer and mesothelioma, with attention to targeted mutations and immunotherapy.
- EGFR‑mutated Non‑Small Cell Lung Cancer
- KRAS‑G12C Non‑Small Cell Lung Cancer
- ALK‑positive Non‑Small Cell Lung Cancer
- Small‑cell Lung Cancer immunotherapy approaches
- Mesothelioma Thoracic treatment strategies
Research integrates molecular profiling, checkpoint inhibition and novel antibody‑drug conjugates.
Hematologic Malignancies
Extensive activity in acute myeloid leukemia, myelodysplastic syndromes, multiple myeloma and various lymphoma subtypes.
- Acute Myeloid Leukemia with or without NPM1 mutation
- Higher‑risk Myelodysplastic Syndromes
- Relapsed/refractory Multiple Myeloma
- Follicular Lymphoma and marginal zone lymphoma
- Diffuse large B‑cell Lymphoma (DLBCL)
Projects target novel targeted agents, cellular therapies and graft‑versus‑host disease mitigation.
Gastro‑Intestinal and Hepatobiliary Oncology
Key interests include colorectal, gastric, esophageal, pancreatic and hepatocellular carcinomas, often with biomarker‑driven selection.
- KRAS‑mutated Colorectal Cancer
- HER2‑positive Gastric Cancer
- BRCA‑mutated Pancreatic Cancer
- Advanced Hepatocellular Carcinoma
- Esophageal Squamous Cell Carcinoma
Therapeutic development emphasizes targeted inhibitors, antibody‑drug conjugates and combination immunotherapy.
Emerging Immuno‑Oncology and Targeted Therapies
Broad exploration of checkpoint inhibition, bispecific antibodies, CAR‑T cells and novel molecular targets across solid and hematologic tumors.
- PD‑1/PD‑L1 blockade in Urothelial Carcinoma
- Bispecific antibodies targeting FGFR2b in gastric and biliary cancers
- CAR‑T cell therapy for refractory B‑cell Lymphoma
- Antibody‑drug conjugates in HER2‑mutated Tumors
- Immune‑modulating agents in Melanoma
Initiatives aim to translate molecular insights into precision immunotherapeutic regimens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.